Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Keytruda
Pharma
Merck’s Lynparza-Keytruda plan sputters in 2nd lung cancer trial
The two flops in metastatic NSCLC, and a separate AstraZeneca setback, don't bode well for Merck's remaining Keytruda-Lynparza study in stage 3 tumors.
Angus Liu
Mar 21, 2024 10:28am
Merck's Keytruda improves survival in cervical cancer trial
Mar 15, 2024 11:31am
GLP-1s on track to take drug sales throne from PD-1 inhibitors
Mar 15, 2024 10:54am
Merck claims digital crown, holding off challenge from AZ, BMS
Mar 15, 2024 10:30am
Merck challenges Johns Hopkins University's Keytruda patents
Mar 14, 2024 7:30am
BMS, overshadowed by ADC rival, wins FDA nod in 1L bladder cancer
Mar 8, 2024 9:56am